AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00381667
Drug: GW642444M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M salt
Trial: NCT00381667
Drug: GW642444H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H salt
Trial: NCT02449343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo p.o. qd
Trial: NCT03211052
Drug: TAK-700 and LHRH agonist
RxNorm normalized name: Somatropin and somatropin agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-700 for 6 months 300mg BD with Leuprorelin Acetate Injections prior to planned prostatectomy
Trial: NCT03272568
Drug: Recombinant FVIII Fc fusion product Eloctate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will get FVIII activity corrected from the baseline level to 100-150% with Eloctate on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 2 hours, 4 hours, 20 hours after the infusion) will be performed to assist with subsequent dosing. 2 total doses of Eloctate likely to be given on day 1 and 3 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Eloctate (with no less than 21 days interval).
Trial: NCT02121613
Drug: Permixon® 160 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration - 160 mg twice daily.
Trial: NCT02121613
Drug: Placebo matching Permixon® 160 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration - twice daily.
Trial: NCT01338298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be sucrose filled capsules that are identical to the active medication. It is double blind so no one will know if the capsule is placebo or aripiprazole.
Trial: NCT02024789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally twice daily, 26 weeks
Trial: NCT02024789
Drug: RG1662
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg (80 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
Trial: NCT02024789
Drug: RG1662
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg (160 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
Trial: NCT03745885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC in the placebo arms and to maintain the blind in the Supaglutide injection arms.
Trial: NCT00299611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, No active ingredient, (1-4tablets/day) for 8 wks during the 2nd phase of the study.
Trial: NCT01301898
Drug: GC1111_0.5mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01301898
Drug: GC1111_1.0mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01301898
Drug: Elaprase_0.5mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03697889
Drug: Naproxen sodium (test product)
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be administered single doses of 275 mg Naproxen sodium (test product) tablet orally.
Trial: NCT03697889
Drug: Naproxen sodium (reference product)
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be administered single doses of 275 mg Naproxen sodium (reference product - Nalgesin) tablet orally.
Trial: NCT00062803
Drug: SR34006
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00062803
Drug: (LMW)heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00062803
Drug: Acenocoumarol VKA
RxNorm normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01252225
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mls of 0.9% saline nebulised followed by 1 ml of 0.9% saline as throat spray
Trial: NCT00285389
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01451437
Drug: MK-8242
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8242 capsules, orally, once per day on Days 1-7 and Days 15-21 of each 28-day cycle (except Cycle 1 Day 7) up to a maximum of 12 cycles. Starting dose will be 30 mg and will be escalated in successive cohorts until maximum tolerated dose (MTD) is established. Beginning at a dose level of ≥120 mg total daily dose (TDD), the dosing regimen will switch to twice daily (BID). Amendment 4 added a 21-day dosing cycle in which MK-8242 would be given BID on Days 1-7 of each cycle, at the assigned dose level.
Trial: NCT03603678
Drug: BAY2253651
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg (500 µg/ml \* 200 µl) BAY2253651 intranasally
Trial: NCT03603678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo dosing
Trial: NCT01826201
Drug: MOL4239
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% MOL4239 ointment to one target lesion twice a day for 28.5 consecutive days
Trial: NCT01826201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days
Trial: NCT00622752
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 X placebo tablets to match EVT 302 5 mg
Trial: NCT03056456
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (SC)
Trial: NCT01071018
Drug: MK2206 once weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 135 mg and 200 mg, once weekly in repeating 4 week cycles.
Trial: NCT00027989
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00975897
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00975897
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03048383
Drug: OnabotulinumtoxinA Injectable Product
RxNorm normalized name: onabotulinumtoxinA Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered to treat facial synkinesis
Trial: NCT03048383
Drug: AbobotulinumtoxinA Injectable Product
RxNorm normalized name: abobotulinumtoxinA Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered to treat facial synkinesis
Trial: NCT03048383
Drug: Incobotulinumtoxin A Injectable Product
RxNorm normalized name: incobotulinumtoxinA Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered to treat facial synkinesis
Trial: NCT00609531
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill once a day for twelve weeks
Trial: NCT01596062
Drug: Simulect®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulect® was provided to the study center in its commercial package containing a powder vial with 20 mg of active product and sterile water for injection. The solution should be used immediately after reconstitution. The infusion was prepared by adding at least 50 mL of physiologic or 5% glucose solution to the reconstituted solution (at least 100 mL for 40 mg of Simulect®). Simulect® was transported and kept in a cold environment (2-8°C) as recommended in the summary of product characteristics (SPC).
Trial: NCT01596062
Drug: Neoral®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoral® was provided to the study center in its commercial package as 10, 25, 50 or 100 mg soft capsules in thermoformed blister packs.
Trial: NCT01596062
Drug: Certican®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Certican® was provided to the study center in its commercial package as 0.75, 0.5 and 0.25 mg tablets in thermoformed blister packs.
Trial: NCT01596062
Drug: Myfortic®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myfortic® was administered orally b.i.d. with a 12-hour interval. Tablets could be taken either with or outside meals but consistently throughout the study. To maintain the integrity of the enteric coating, tablets were not to be crushed. Myfortic® treatment was initiated either preoperatively or within 24 hours post transplantation according to local practice in each center. Starting dose was to be 2160 mg/day (1080 mg b.i.d.) for at least 2 weeks and for at most 4 weeks. Patients were then to receive 1440 mg/day (720 mg b.i.d.) until the end of the study. Myfortic® was administered as concomitant treatment to all patients, using the same regimen for all 3 study groups. It was provided to the study center in its commercial package as 180 and 360 mg gastro-resistant tablets.
Trial: NCT01596062
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid i.v. therapy could be administered peri or per operatively according to local practice in each center with the same scheme for each patient in the center. Oral corticotherapy was to be initiated rapidly, within one week following transplantation, with a minimal dose of 20 mg/day. Thereafter, the dose was to be decreased according to local practice but oral corticosteroids were to be continued throughout the study with a minimal dose of 5 mg/day.
Trial: NCT02611596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 24 weeks
Trial: NCT00943072
Drug: Sham
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly sham intravitreal injection out to Week 24 Primary Endpoint
Trial: NCT00526916
Drug: [C-11]PBR28
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04682119
Drug: LY3526318
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04682119
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT02405442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match andecaliximab administered via SC injection
Trial: NCT03241030
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
Trial: NCT03241030
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
Trial: NCT00444678
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2500 mg, po bid x 7 days every two weeks
Trial: NCT00504946
Drug: prednisone, lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone+ 0.3mg lactose
Trial: NCT00504946
Drug: prednisone, colecalciferol, lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone + 1000j colecalciferol + 0.3mg lactose
Trial: NCT00504946
Drug: lactose
RxNorm normalized name: Lactose
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~0.3mg lactose
Trial: NCT00504946
Drug: lactose
RxNorm normalized name: Lactose
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen immunotherapy (build-up phase)premedication with 0,3mg lactose once daily at bedtime
Trial: NCT02713607
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given doxycycline to acne subjects
Trial: NCT01816334
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00118209
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT00118209
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV or CIVI
Trial: NCT04664764
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal insulin comparison
Trial: NCT02180659
Drug: placebo implants
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02180659
Drug: sublingual placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01872832
Drug: RDEA3170 and Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00640224
Drug: drospirenone/ethinyl estradiol
RxNorm normalized name: DROSPIRENONE/ETHINYL ESTRADIOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tab (3mg/30mcg) daily for 6 months
Trial: NCT02535156
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose Placebo
Trial: NCT01254162
Drug: MTC896 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% w/w gel applied daily for 28 days to the forehead
Trial: NCT01667419
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to vemurafenib were administered orally as per the schedule specified in the respective arm.
Trial: NCT01343381
Drug: Hepalean Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 units per kilogram bolus prior to initiation of CPB
Trial: NCT01343381
Drug: PPC Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 unit per kilogram bolus prior to initiation of CPB
Trial: NCT00157482
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03632408
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01839604
Drug: AZD9150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion over 3 hours.
Trial: NCT01641419
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of saline added to 30 ml of ropivacaine 0.5% solution for nerve block
Trial: NCT00066586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo once daily x 1 year
Trial: NCT03337490
Drug: Placebo 0% Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects on Placebo will receive a single dose, 117g, during the study to be applied at baseline.
Trial: NCT01105546
Drug: recombinant activated factor VII
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 µg/kg/day i.v.
Trial: NCT01105546
Drug: recombinant activated factor VII
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution
Trial: NCT01689532
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Between sirukumab injections, placebo SC at Weeks 2, 6, and every 4 weeks through Week 52.
Trial: NCT00644007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as a substitute of SK3530 100mg
Trial: NCT00644007
Drug: SK3530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SK3530 100 mg
Trial: NCT00778193
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet 500mg BID for 8 days
Trial: NCT00778193
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 capsule 200mg QD for 8 days
Trial: NCT00778193
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule BID for 8 days
Trial: NCT04150107
Drug: ORMD-0801 Treatment B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B: 8 mg (8 mg capsule) three times a day (TID) 45-90 minutes before meals
Trial: NCT00111007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 2 tablets bid Study Days 2-19
Trial: NCT00040209
Drug: JP 1730
RxNorm normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02782858
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly IV repeated dose
Trial: NCT00040209
Drug: IV Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01412294
Drug: Capecitabine, Cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Capecitabine Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle.
Trial: NCT01565655
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01419405
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50-90 min: TCI 0.6 ng/mL, 100-140 min: 1.2 ng/mL, 150-190 min: TCI 2.4 ng/mL
Trial: NCT01419405
Drug: sugar pill, saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hard capsule, 150 mg, 2 times, 2 days, saline infusion
Trial: NCT02709538
Drug: GSP 301 Placebo NS pH 3.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 spray in each nostril twice daily for 52 weeks
Trial: NCT02709538
Drug: GSP 301 Placebo NS pH 7.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 spray in each nostril twice daily for 52 weeks
Trial: NCT02160041
Drug: BGJ398
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
Trial: NCT00540410
Drug: Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants tablets: AS 25/AQ 67,5 mg Toddlers tablets: AS 50/AQ 135 mg Once daily, dose according to bodyweight range Duration of treatment: 3days Children tablets: AS 100/AQ 270 mg
Trial: NCT00540410
Drug: Coartem® (arthemether+ lumefantrine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, 20/120 mg, oral route, twice daily, dose according to bodyweight range.~Duration of treatment: 3 days
Trial: NCT02059291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to canakinumab solution for subcutaneous injection
Trial: NCT06275633
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Medicine response
Trial: NCT01240109
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * propofol group : propofol effect site-TCI 2-4mcg/ml + remifentanil effect site-TCI 2-4ng/ml~* sevoflurane group: sevoflurane end-tidal concentration 0.5-1.0 MAC + remifentanil effect site-TCI 2-4ng/ml
Trial: NCT03785223
Drug: Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11 no further dose changes will occur.
Trial: NCT03614052
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet 1 tablet per day for 5 days before ureteroscopic treatment of urolithiasis
Trial: NCT02161692
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03930615
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered as tablets matched to LET or as inactive (saline or dextrose) intravenous infusion.
Trial: NCT04611152
Drug: KSI-301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal Injection
Trial: NCT01281475
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa/Carbidopa (4:1)~Dosages are based on levodopa.~Subjects randomized to the levodopa arm will receive a levodopa dose of 5 mg/kg/day in the first 2 weeks of the study, a levodopa dose of 10 mg/kg/day in the second 2 weeks of the study, and a levodopa dose of 15 mg/kg/day (up to a maximum of 800 mg per day) for the remaining duration of the study.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day.
Trial: NCT01281475
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo contains excipients similar to those in the active drug, but it does not contain levodopa or carbidopa.
Trial: NCT02490345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo